Search alternatives:
latest decrease » largest decrease (Expand Search), greatest decrease (Expand Search), largest decreases (Expand Search)
teer decrease » greater decrease (Expand Search)
web decrease » we decrease (Expand Search), step decrease (Expand Search), _ decrease (Expand Search)
_ latest » _ latent (Expand Search), _ largest (Expand Search), _ late (Expand Search)
_ web » _ wet (Expand Search)
latest decrease » largest decrease (Expand Search), greatest decrease (Expand Search), largest decreases (Expand Search)
teer decrease » greater decrease (Expand Search)
web decrease » we decrease (Expand Search), step decrease (Expand Search), _ decrease (Expand Search)
_ latest » _ latent (Expand Search), _ largest (Expand Search), _ late (Expand Search)
_ web » _ wet (Expand Search)
-
1
-
2
Y-27632 collaborated with BA to attenuate the increase in the integrity and decrease in the permeability of epithelial barrier injury induced by LPS in Caco2 monolayers.
Published 2024“…<p>(<b>A)</b> Y-27632 collaborated with BA to attenuate the effect of LPS on TEER in Caco2 cells on days 1–22. …”
-
3
-
4
A summary of the included study characteristics.
Published 2025“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
-
5
Apoptosis inhibitor prevented the decrease of IIL ESP-induced TJs expression and alleviated barrier disruption of Caco-2 monolayer.
Published 2025“…<p><b>A:</b> Apoptosis inhibitor Z-VAD-FMK pretreatment increased the IIL ESP-decreased TEER. …”
-
6
List of Included studies.
Published 2025“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
-
7
The search strategy in three databases.
Published 2025“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
-
8
NIH score.
Published 2025“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
-
9
List of excluded studies.
Published 2025“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
-
10
The effect of HA digestion and HA replenishment alone or with CS on barrier function measured by TEER.
Published 2025“…In (B) and (C) each point represents a mean ± standard deviation. (B) Hyaluronidase treatment (n = 8) gradually increased TEER, this significantly differed from the untreated group (n = 8) and the PS treated group (n = 8) (p < 0,001). …”
-
11
BA attenuated the decrease in the integrity and increase in the permeability of the epithelial barrier injury induced by LPS in Caco2 cell monolayers.
Published 2024“…<p>(<b>A)</b> Changes in TEER with increasing culture time on days 1–22. …”
-
12
Image 1_Using sodium glycodeoxycholate to develop a temporary infant-like gut barrier model, in vitro.pdf
Published 2025“…</p>Results<p>Our research demonstrates that GDC decreases Caco-2/HT29-MTX Trans-Epithelial Electrical Resistance (TEER) and increases paracellular permeability, without inflammation or cytotoxicity. …”
-
13
Table 1_Using sodium glycodeoxycholate to develop a temporary infant-like gut barrier model, in vitro.docx
Published 2025“…</p>Results<p>Our research demonstrates that GDC decreases Caco-2/HT29-MTX Trans-Epithelial Electrical Resistance (TEER) and increases paracellular permeability, without inflammation or cytotoxicity. …”
-
14
Image 5_Using sodium glycodeoxycholate to develop a temporary infant-like gut barrier model, in vitro.pdf
Published 2025“…</p>Results<p>Our research demonstrates that GDC decreases Caco-2/HT29-MTX Trans-Epithelial Electrical Resistance (TEER) and increases paracellular permeability, without inflammation or cytotoxicity. …”
-
15
Image 4_Using sodium glycodeoxycholate to develop a temporary infant-like gut barrier model, in vitro.pdf
Published 2025“…</p>Results<p>Our research demonstrates that GDC decreases Caco-2/HT29-MTX Trans-Epithelial Electrical Resistance (TEER) and increases paracellular permeability, without inflammation or cytotoxicity. …”
-
16
Image 2_Using sodium glycodeoxycholate to develop a temporary infant-like gut barrier model, in vitro.pdf
Published 2025“…</p>Results<p>Our research demonstrates that GDC decreases Caco-2/HT29-MTX Trans-Epithelial Electrical Resistance (TEER) and increases paracellular permeability, without inflammation or cytotoxicity. …”
-
17
Image 3_Using sodium glycodeoxycholate to develop a temporary infant-like gut barrier model, in vitro.pdf
Published 2025“…</p>Results<p>Our research demonstrates that GDC decreases Caco-2/HT29-MTX Trans-Epithelial Electrical Resistance (TEER) and increases paracellular permeability, without inflammation or cytotoxicity. …”
-
18
-
19
-
20